vaccine test done by Oxford University scientists

vaccine test called AZD1222

The vaccine test called AZD1222, which jointly developed by AstraZeneca and Oxford University scientists. It is generally safe (fever and headache are the most severe, but can be controlled), and antibody and T cell immune responses are visible.

COVID-19 is still a bigger issue, and long-term follow-up trials needed to confirm this (and are ongoing).

patience is not the keyword for this pandemic.

However, patience is not the keyword for this pandemic. Although Oxford has not approved it before, the United Kingdom has ordered 100 million doses of vaccine. Although Oxford has previously stated that it may be approved as early as September.

coronavirus vaccine
coronavirus vaccine

Therefore, the early observation of the data is this:

The Phase 1/2 trial saw about 500 patients receiving the AZ/Oxford vaccine. Which is also known as ChAdOx1 nCoV-19, and the results performed with approximately the same number of people.

For the AZ vaccine, the antibody against the SARS-CoV-2 peak protein peaked on the 28th day and increased until the 56th da. Indicating an immune response against the virus. Recently, many so-called T cells (a type of white blood cell) have also made; here, the vaccine level of T cells reaches a peak 14 days after vaccination and is still present two months later.

median age

The median age is 35 years old, much younger than the most needed age group (ie 70 years and older). And most people receiving the AZ vaccine have experienced pain, headache, fever, and fatigue, although there does not seem to be any symptoms serious. These are usually controlled with paracetamol.

This is a different method from Pfizer and its partners BioNTech, CureVac, and Moderna and the other three other major COVID-19 vaccine producers that use mRNA. This method may prove to be faster, but it has been I have not seen the use of drugs or vaccination methods approved by this MOA.

In the past week, AstraZeneca’s share price has been rising on the highly anticipated data, but when the publication of The Lancet came out in the afternoon British time, its share price fell by several percentage points. The company said it would not profit from vaccines during the pandemic.

Recent Articles:

Leave a Comment